• 17-AAG packaged and labeled in glass bottle.

click on thumbnail to zoom
SKU: A061

Size  
Quantity:
  Click 'Bulk Order' for 10 or more
Price: make selection(s)
Description

17-AAG (17-N-Allylamino-17-demethoxygeldanamycin) is a geldanamycin- derived anti-tumor agent currently used in cancer research. It is an inhibitor of heat shock protein 90.

    CAS Number

    75747-14-7

    Molecular Formula

    C31H43N3O8

    Molecular Weight

    585.69

    Mechanism of Action

    17-AAG targets and inactivates Hsp90 (heat shock protein 90), which is expressed in certain types of leukimia and lymphomas as well as solid tumors.

    Storage Conditions

    -20 ┬░C

    Tariff Code

    2941.90.5000

Applications

    Cancer Applications

    17-AAG has been shown to induce cell-cycle arrest and apoptosis in cultured ALCL cells irrespective of ALK expression. In addition, 17-AAG has shown promising results in the treatment of uveal melanoma through inhibition of HSP-90 in tandem with c-Kit inhibition.

    Eukaryotic Cell Culture Applications

    Canine osteosarcoma is highly resistant to chemotherapy thus additional information resistance mechanisms is needed. An investigation with 17-AAG in canine osteosarcoma cell lines was undertaken to understand the relationship between cell death, autophagy and mitophagy in regulating cancer cell viability and death. Authors tested 2 cell lines (D22, and D17 from primary and metastatic tumors respectively. It was found that17-AAG caused a simultaneous increase in apoptosis, autophagy, and mitophagy was observed in the D22 cell lines, but only slight apoptosis in the D17 cell line. This study revealed that a treatments based on pro-apoptotic chemotherapy with autophagy regulators could benefit from in-vitro screening, since there are differences in cell responses based on cell type (Massimini et al, 2017).

Specifications

    Form

    Powder

    Appearance

    Purple powder

    Source

    Synthetic

References

    References

    Hawkins LM, Jayanthan AA, Narendran A (2005)  Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatr Res. 57(3):430-437

    Massimini M et al (2017)  17-AAG and apoptosis, autophagy, and mitophagy in canine osteosarcoma cell lines. Vet. Pathol. 54(3):405-412

    Radujkovic A et al (2005)  Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. Leukemia. 19(7):1198-1206

Other Items In This Category